Your browser doesn't support javascript.
loading
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina, Thierry Jo; Canioni, Danielle; Copie-Bergman, Christiane; Recher, Christian; Brière, Josette; Haioun, Corinne; Berger, Françoise; Fermé, Christophe; Copin, Marie-Christine; Casasnovas, Olivier; Thieblemont, Catherine; Petrella, Tony; Leroy, Karen; Salles, Gilles; Fabiani, Bettina; Morschauser, Franck; Mounier, Nicolas; Coiffier, Bertrand; Jardin, Fabrice; Gaulard, Philippe; Jais, Jean-Philippe; Tilly, Hervé.
Afiliação
  • Molina TJ; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Canioni D; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Copie-Bergman C; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Recher C; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Brière J; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Haioun C; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Berger F; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Fermé C; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Copin MC; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Casasnovas O; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Thieblemont C; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Petrella T; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Leroy K; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Salles G; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Fabiani B; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Morschauser F; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Mounier N; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Coiffier B; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Jardin F; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Gaulard P; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Jais JP; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
  • Tilly H; Thierry Jo Molina, Danielle Canioni, and Jean-Philippe Jais, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants-Malades, Université Paris Descartes, EA 7324, Sorbonne Paris Cité; Josette Brière and Catherine Thieblemont, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité; C
J Clin Oncol ; 32(35): 3996-4003, 2014 Dec 10.
Article em En | MEDLINE | ID: mdl-25385729
PURPOSE: To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) compared with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). PATIENTS AND METHODS: Using immunohistochemistry, expression of CD10, BCL6, MUM1, MYC, and BCL2 and coexpression of MYC/BCL2 were examined. The interaction effects between each biomarker and treatment arm on survival were studied in a restricted model and a full model incorporating clinical parameters. RESULTS: Among the 379 patients analyzed in the trial, 229 tumors were evaluable for germinal center B-cell-like (GCB)/non-GCB subclassification according to the Hans algorithm. Among all the biomarkers, only the interaction between the Hans algorithm and the treatment arm was significant for progression-free survival (PFS) and overall survival (OS) in univariable (PFS, P = .04; OS, P = .01) and multivariable (PFS, P = .03; OS, P = .01) analyses. Non-GCB tumors predicted worse PFS (hazard ratio [HR], 3.21; 95% CI, 1.29 to 8.00; P = .01) and OS (HR, 6.09; 95% CI, 1.37 to 27.03; P = .02) among patients treated with R-CHOP compared with patients who received R-ACVBP, whereas there were no significant survival differences between these regimens among patients with GCB tumors. CONCLUSION: The survival benefit related to R-ACVBP over R-CHOP is at least partly linked to improved survival among patients with non-GCB DLBCL. Therefore, the Hans algorithm could be considered a theragnostic biomarker for selecting young patients with DLBCL who can benefit from an intensified R-ACVBP immunochemotherapy regimen.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos